7093 results about "Urology" patented technology

A urine collection device includes a collection member extending from a proximal end to a distal end. The proximal end includes an opening that provides access to an internal cavity of the collection member. The internal cavity includes a first chamber in fluid communication with a second chamber. The urine collection device includes a spacer in the second chamber, a first attachment member extending from a bottom wall of the collection member at the proximal end., a second attachment member extending from a top wall of the collection member at the proximal end, and an outlet for egressing urine from the internal cavity of the collection member. The first attachment member defines an aperture. The collection member is suitable to (i) direct urine from the first chamber to the second chamber and (ii) direct the urine in the second chamber distally toward the outlet.

A urine diversion device includes a diversion member extending from a proximal end to a distal end. The diversion member includes an opening that is configured to provide access to an internal cavity of the diversion member. The urine diversion device also includes a spacer in the internal cavity. The spacer includes one or more preferential separation regions in at least one of a first major surface or a second major surface. The urine diversion device also includes one or more attachment members configured to couple the diversion member to a user, and an outlet for egressing urine from the internal cavity of the diversion member. The diversion member is suitable to direct urine toward the outlet.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The invention discloses a method for predicting abnormal indexes after thoracic surgery, and relates to the technical field of medical treatment, and the main scheme is as follows: obtaining historical data related to thoracic surgery and preoperative examination, basic information, intraoperative and postoperative recovery data of a patient, and respectively calculating a preoperative comprehensive value, a basic information evaluation value, an intraoperative risk index and a postoperative recovery index; further obtaining a predicted postoperative infection index and a predicted cardiopulmonary function index; calculating a postoperative infection index threshold value and a cardiopulmonary function index threshold value according to the historical data; by comparing a prediction index with a threshold value, triggering corresponding early warning and formulating postoperative management and intervention strategies of different levels, the postoperative rehabilitation quality and safety of a thoracic surgery patient are improved, a comprehensive method is provided for postoperative management of the thoracic surgery patient, risks can be found in time, targeted measures can be taken, and the postoperative rehabilitation safety of the thoracic surgery patient is improved. The operation success rate and the patient life quality are improved.

This disclosure relates to a method of treating depression and / or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

A urinary output monitoring system including a urine collection assembly coupled with an automated urinary output monitoring device. The urine collection assembly includes a drainage tube, an accumulator coupled with the drainage tube, and a urine collection container fluidly coupled with the accumulator. The automated urinary output monitoring device operatively is coupled with the urine collection container. Logic determines a volume of urine collected in the container based on a signal from a load cell of the monitoring device. A vacuum pump coupled with the accumulator generates a flow of air that the drags the urine along the drainage tube to the accumulator. The accumulator separates the flow of air from the urine. The flow of air enters the drainage tube by way of a female external urinary catheter.

The invention discloses an effect evaluation method for a non-dialysis diabetic kidney disease, which comprises the following steps: monitoring the change trend of data by collecting renal function related data of a patient, and generating a basic data set; a dynamic nonlinear weighted regression algorithm is adopted to analyze the multi-dimensional renal function data, data weights are dynamically adjusted, and influence weights of different time periods are distributed according to the change mode of the illness state; the data influence is adjusted in real time through a time correlation mechanism, and a disease assessment curve is generated; according to the method, historical data and real-time data are combined, a patient condition trend line and a prediction result are generated, personalized treatment feedback is output, and intervention suggestions are provided for clinicians based on long-term prognosis prediction. The method is suitable for disease monitoring and treatment feedback of patients with non-dialysis diabetic kidney diseases.

The invention relates to the technical field of diagnosis, in particular to a diagnosis and treatment auxiliary system and method for the obstetrics and gynecology department, and the system comprises a parameter collection module, a feature offset recognition module, a feature reconstruction module, a collaborative trend recognition module and a diagnosis and treatment suggestion generation module. According to the system and the method, the body temperature, the heart rate, the pulse, the blood pressure and the image edge density are synchronously acquired and the timestamps are bound, so that a structured diagnosis and treatment data unit is formed, the time sequence comparison capability of multi-source information is effectively improved, and potential risk points can be positioned and feature tags can be constructed based on a numerical value offset identification and synchronous index combined judgment mechanism; according to the method, physical signs, images and laboratory data are normalized and fused into three-dimensional vectors, cross-dimensional feature linkage expression is achieved, the dynamic insight ability to pathological state changes is improved by screening features with large variation amplitude and long duration time and judging trend consistency, and the accurate response to the fetal risk state is enhanced by combining a specific trend combination matching rule.

Disclosed herein is urinary output monitoring system including a urinary collection device having a flow meter in communication with a monitor. The urinary collection device catheter includes a urine collection bag, a drainage tube and a urinary catheter. A console of the flow meter wirelessly communicates with a console of the monitor. The monitor depicts urine flow rate information on a display and wirelessly transmits urine flow rate information to an EMR system. The flow meter includes a flow meter identifier and the system links the urine flow rate information to the flow meter identifier. The monitor further links the flow meter identifier with a patient identification from the EMR system and depicts the patient identification on the display.

Methods of treating patients with chronic thyroid eye disease are provided for herein, such as by administering antibodies and compositions that bind to and / or antagonize IGF-1R.

The invention provides an early-stage automatic identification method and system for acute kidney injury related to cardiac surgery, and relates to the technical field of physiological parameter detection. The method comprises the following steps: acquiring average arterial pressure, cardiac blood discharge volume, central venous pressure and blood oxygen saturation, regularly recording and extracting data of adjacent time points, calculating a variation range, screening a mutation region, judging whether a reference range is exceeded or not, analyzing a multi-parameter synchronous variation condition, and marking a hemodynamics abnormal state. According to the method, abnormal changes of hemodynamics and urine metabolism are accurately recognized through real-time monitoring and multi-parameter analysis, the urine flow rate and the metabolite excretion rate are combined, misjudgment of a single index is avoided, the fineness of renal function change analysis is improved, the high-risk time period is accurately positioned through time cross comparison, the diagnosis accuracy is improved, and the diagnosis accuracy is improved. Trend analysis and risk grade division enable the change of the illness state to be more visual, and a real-time early warning system effectively monitors the fluctuation trend, optimizes clinical management and improves the timeliness of medical response.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a subject having an anemia associated with chronic kidney disease and / or kidney disease in a subject that has a level of glomerular filtration rate lower than one or more thresholds.

The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

The invention discloses a preparation method and application of a tension sensor for monitoring cortisol in sweat. According to the scheme, on the basis of a stretchable electrode (SWNTs / PDMS) which is prepared by patterning in a manner that a single-walled carbon nanotube is subjected to suction filtration and transfer printing on polydimethylsiloxane, cortisol is used as an imprinting molecular template by utilizing an electrochemical deposition technology, and Prussian blue (PB) and pyrrole (Py) are electrically polymerized to prepare an electrochemical sensor of a molecularly imprinted polymer (MIP), so that the change of the concentration of cortisol in sweat can be monitored in real time; a reliable and practical method is provided for rapid and pressure-free pressure monitoring. A scanning electron microscope is used for electrode modification morphology characterization, and an electrochemical workstation is used for electrode sensing performance characterization. The sensor realizes the function of dynamically monitoring the day and night change rule of cortisol in sweat, and has the characteristics of real-time detection, high sensitivity and selectivity and good stability.

The invention discloses a mutation site combination for detecting susceptible genes of a type 2 diabetes kidney disease, which comprises eight SNP sites, application of primers for detecting the SNP sites in preparation of products for evaluating the risk of the type 2 diabetes kidney disease, and a primer kit for detecting the SNP site combination related to the type 2 diabetes kidney disease. According to the present invention, the importance of the pathogenesis relationship between the SNP site combination and the type 2 diabetes kidney disease is comprehensively evaluated by detecting the SNP site combination, the accuracy of the SNP site analysis is improved, and the provided kit provides the simple and effective auxiliary means for detecting the risk of the type 2 diabetes kidney disease; the method is suitable for prediction, prevention and individualized diagnosis and treatment of patients with the type 2 diabetes kidney disease.

The invention discloses a simulation training method and system for a minimally invasive surgery in the obstetrics and gynecology department, and relates to the technical field of virtual reality, and the method comprises the following steps: obtaining related medical data on a patient in the obstetrics and gynecology department, and carrying out the preprocessing of a medical image; the processed two-dimensional image is converted into a three-dimensional model, an operation scene is constructed, and the anatomical model of the patient in the obstetrics and gynecology department and the scene are fused; generating a plurality of operation planning schemes, calculating an operation difficulty coefficient Nd of each operation scheme, and determining an optimal operation scheme according to the size of the operation difficulty coefficient Nd; establishing an interactive interface between the doctor and the virtual operation scene, and recording various indexes of the doctor in the simulated operation process; after the simulated operation is finished, the operation is analyzed, an operation analysis report is generated, and the simulated operation is evaluated and optimized; through virtual reality minimally invasive surgery simulation, the misoperation risk in a real surgery can be reduced, so that the operation error rate in the surgery is reduced.

The invention belongs to the technical field of biological medicines, and particularly relates to a composition for treating male erectile dysfunction and application thereof. The oyster polypeptide is prepared by enzymolysis of oyster protein, can effectively promote proliferation of testicular interstitial cells, enhance and improve sexual desire and improve sexual behavior, has certain clinical application value, has the advantages of simple preparation, easy absorption and the like, and is easy to popularize and apply.

The disclosure provides methods of identifying a subject for treatment with an anti-ox-LDL antibody. The disclosure also provides methods of treating a subject with an anti-ox-LDL antibody, wherein the subject has been identified to as a candidate for anti-oxLDL antibody therapy. The methods described herein use computed tomography to identify subjects who are a candidate for anti-oxLDL antibody therapy, wherein a subject may be determined to be a candidate for anti-oxLDL antibody therapy by evaluating their fat attenuation index (FAI), perivascular adipose tissue (PVAT), pericoronary adipose tissue, FAI score, FAI percentile, or CaRi-Heart® Risk score.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The invention belongs to the field of biomedicine, and particularly relates to application of CRYL1 protein in preparation of a product for evaluation, diagnosis or auxiliary diagnosis of postoperative recurrence risk of calcium oxalate kidney stone combined with renal nipple calcium spot, and the sequence of the CRYL1 protein is shown as SEQ ID NO.1. The invention discovers that the expression of the CRYL1 protein in renal tubules and collecting tube cells of renal papillary calcium spot tissues is reduced for the first time, and tests prove that the urine CRYL1 protein is a predictive factor and a predictive marker for postoperative recurrence of a patient with CaOx kidney stone combined with renal papillary calcium spot. The CRYL1 protein detection kit is further researched and developed to be used for detecting or evaluating the postoperative recurrence risk of patients suffering from CaOx kidney stone combined with renal nipple calcium spots, personalized follow-up visit and prevention schemes of the patients are promoted, and the CRYL1 protein detection kit has huge clinical application prospects.

The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

The invention belongs to the technical field of kidney histopathology and immunological evaluation, and particularly relates to a kidney pathology detection kit, a detection method and application, the detection kit comprises 37 rare metal element labeled monoclonal antibodies combined with antigens of in-situ tissue cells, and the detection method comprises the following steps: (1) collecting a sample to be detected, preparing a pre-dyed paraffin section; (2) mixing 37 monoclonal antibodies labeled by rare metal elements, and carrying out antibody staining on various antigen targets on the surfaces of cells in the in-situ tissue; (3) carrying out nucleus DNA staining on the stained tissue sample; and (4) detecting the stained tissue sample through an imaging mass spectrum flow system, and collecting original information data through laser spot firing. The method is an analysis method for fine grouping identification and relative quantification of structural cells, immune cells and pathological injury cells in the clinical nephropathy sample in-situ tissue. And auxiliary diagnosis information is provided for diagnosis, grading, treatment and prognosis detection of various clinical nephropathy.

Disclosed herein are pharmaceutical compositions to treat, prevent, reduce the incidence of, or reduce the severity of hepatic steatosis comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the incidence of, or reducing the severity of hepatic steatosis comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

The invention discloses a diabetic nephropathy risk assessment and prediction system based on platelet indexes, and particularly relates to the technical field of disease risk prediction, which comprises a platelet index acquisition module, a drug use data acquisition module, a drug intervention assessment module, an index correction module, a clustering analysis module and a diabetic nephropathy risk assessment module, the method comprises the following steps: acquiring platelet related detection indexes and historical medication data of a patient, calculating a drug intervention influence index and generating a correction factor, realizing platelet index reverse reduction correction by adopting a convolutional neural network model, determining a similar group in combination with clustering analysis, and dynamically evaluating the risk of diabetic nephropathy based on the average morbidity of the group. Personalized accurate prediction is realized; the platelet index correction accuracy is improved, individualized drug intervention elimination is achieved, the similar population clustering analysis precision is enhanced, diabetic nephropathy risk prediction is dynamically adjusted in combination with comprehensive scores, and the early screening and individualized intervention effects are improved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory lactase-like protein (LCTL) as a diagnostic marker in preparation of a diagnostic kit for chronic kidney diseases. According to the present invention, the secretory form of the LCTL is found for the first time, the secretory LCTL content in the human serum is detected by using the existing commercial ELISA kit for the first time, and the further research finds that the secretory LCTL content in the serum of the chronic kidney disease patient is significantly reduced compared with the normal person; and the content of the LCTL in the serum is obviously related to the renal function impairment degree and proteinuria degree of the patient, so that the application of the secretory LCTL in preparing the biomarker for diagnosing the chronic kidney disease is provided for the first time. The invention provides a new method for chronic kidney disease diagnosis, and has important clinical significance and commercial value.